Print ISSN: 1680-2594

Online ISSN: 2264-2522

Keywords : Valsartan


Comparative Effects of Telmisartan versus Valsartan on serum Leptin level, in hypertensive type 2 diabetes mellitus patients

Najlaa Saadi Ismael; Fathel Abaas Al-hamamy

Iraqi Journal of Pharmacy, 2014, Volume 14, Issue 1, Pages 95-104
DOI: 10.33899/iphr.2019.161199

Objective: The aim of this study was to compare the effects of telmisartan and valsartan onblood pressure and serum leptin in hypertensive type 2 diabetesMellitus patients.
Study design:A randomized control comparative clinical trial with open label design.
Study period: From 1st  February, 2012 to 30th March, 2013.
Patients and method: Eighty eight type 2 diabetic hypertensive  patients were randomly assigned to received either telmisartan (n = 46)  or valsartan (n = 42) with body mass index (BMI) 31.52±4.73 kg/m², 30.39±3.95 kg/m² respectivly. Forty one diabetic normotensive patients (n=41), age, sex, BMI, duration of diabetic  disease, duration of diabetic treatment matched to the diabetic hypertensive  patients groups were kept as control group. blood pressure (BP), leptin levels were measured at baseline and after 2 months of treatment.
Results: The study showed a significant higher systolic blood pressure (SBP), diastolic blood pressure (DBP) and serum leptin in the diabetic hypertensive patients before starting therapy as compared with the diabetic normotensive patients. Both telmisartan and valsartan significantly reduced serum leptin and BP. More reduction in DBP seen with valsartan  than with telmisartan.
Conclusion: Monotherapy with telmisartan and valsartan produce a beneficial reduction effects on BP and reduce leptin level. The improvement of leptin sensitivity may play a role directly or indirectly in the induction of hypertension control.

Effects of valsartan vs captopril on some renal function tests in hypertensive patients

Shamil Hashim Othman

Iraqi Journal of Pharmacy, 2012, Volume 12, Issue 1, Pages 56-64
DOI: 10.33899/iphr.2012.62344

Objectives: To investigate the effects of valsartan and captopril on some renal function tests (RFTs) in patients with essential hypertension.
Patients and methods: A total of 40 patients with stage I essential hypertension were recruited and investigated for RFTs which include, blood urea, serum creatinine, creatinine clearance, serum sodium and serum potassium. The patients were divided into 2 groups, namely the valsartan group which consisted of 20 patients and the captopril group which consisted of 20 patients. The patient groups were followed- up for 8 weeks during which RFTs were measured before starting therapies and at the end of the follow-up period using commercially available kits. The patient groups were compared with a control group consisted of 30 apparently healthy subjects.
Results: The RFTs at baseline in both patient groups were found elevated as compared to the control group (p < 0.001), except for serum potassium concentration which was comparable . The RFTs in patient groups were comparable before and after therapies.
Conclusion: The use of valsartan and captopril for 8 weeks in hypertensive patients has no adverse effects on RFTs.